Drugs / PF-08046876
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07090499 | Aug 2025 → Jul 2028 expected | esophageal adenocarcinoma, esophageal squamous cell carcinoma, gastroesophageal junction adenocarcinoma, head and neck squamous cell carcinoma +4 | Pfizer | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-08046876 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07090499 ↗ |
| Route | Intravenous | “Intravenous administration” NCT07090499 ↗ |